newsfilter
← Latest News
GlobeNewswire·

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growthThe FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for